[Safety and efficacy of enteral nutritional suspension (TPF-FOS) JEVITY in acute stroke].
OBJECTIVE
To evaluate the safety and efficacy of enteral nutritional suspension (TPF-FOS) JEVITY in acute stroke patients.


METHODS
A multicenter, prospective, post-marketing observational study was conducted. A total of 103 acute stroke patients with dysphagia received a 10-day regimen of enteral nutritional suspension (TPF-FOS) JEVITY via nasal gastric tube feeding. The parameters of serum prealbumin, serum albumin and percentage of abnormal blood glucose were evaluated and compared. The incidence of adverse events was recorded. The data were analyzed by paired t-test.


RESULTS
At the end of the study in comparison with the baselines, the serum prealbumin increased significantly (213 mg/L ± 56 mg/L vs 219 mg/L ± 66 mg/L) and serum albumin decreased markedly (38 g/L ± 5 g/L vs 36 g/L ± 5 g/L) but stayed stable during tube feeding. No significant changes were found in percentage of abnormal blood glucose (40.78% vs 38.76%), body mass index (23.1 kg/m(2) ± 3.0 kg/m(2) vs 22.8 kg/m(2) ± 2.9 kg/m(2)) and C-reactive protein (13 mg vs 14 mg). Only 18 adverse events were related with the study product. And most of them were gastrointestinal reactions.


CONCLUSIONS
Enteral nutritional suspension (TPF-FOS) JEVITY may increase the level of serum prealbumin in acute stroke patients and improve the patient nutritional status. With a low incidence of adverse events, it is a preferred option for enteral nutrition formulas in stroke.
Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
Bin
B
Peng
Ying-ying
YY
Su
Li-ying
LY
Cui
Shao-shi
SS
Wang
Yang-tai
YT
Guan
Dong
D
Zhou
He-qing
HQ
Zhao
D000368:Aged; D000369:Aged, 80 and over; D004750:Enteral Nutrition / Q000009:adverse effects* / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D020521:Stroke / Q000628:therapy*